Summit Therapeutics Inc. Increase (Decrease) in Accounts Payable
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Accounts Payable of $2.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-07-23
- Summit Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$3.91M, a 121.79% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $6.80M, a 1810.67% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$2.15M, a 240.29% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$839.00K.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2025 was $15.30M, a 659.45% increase from fiscal 2024.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2024 was $2.02M, a 10.96% decline from fiscal 2023.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.26M.
- Summit Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2022 was -$4.13M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 11 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $2.90M 10-Q · filed 2026-07-23 | $750.00K derived: sum of 3 quarters · filed 2026-07-23 | -$89.00K derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2026-03-31 | $6.80M 10-Q · filed 2026-04-30 | $4.66M derived: sum of 2 quarters · filed 2026-04-30 | $3.82M derived: sum of 3 quarters · filed 2026-04-30 | $21.75M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$2.98M derived: sum of 2 quarters · filed 2026-02-23 | $14.95M derived: sum of 3 quarters · filed 2026-07-23 | $15.30M 10-K · filed 2026-02-23 | ||
| 2025-09-30 | -$839.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $17.09M derived: sum of 2 quarters · filed 2026-07-23 | $17.45M 10-Q · filed 2025-10-20 | $18.98M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-06-30 | $17.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $18.29M 10-Q · filed 2026-07-23 | $19.82M derived: sum of 3 quarters · filed 2026-07-23 | $19.64M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-03-31 | $356.00K 10-Q · filed 2026-04-30 | $1.89M derived: sum of 2 quarters · filed 2026-04-30 | $1.70M derived: sum of 3 quarters · filed 2026-04-30 | -$1.33M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.35M derived: sum of 2 quarters · filed 2026-02-23 | -$1.69M derived: sum of 3 quarters · filed 2026-02-23 | $2.02M 10-K · filed 2026-02-23 | ||
| 2024-09-30 | -$181.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | -$3.22M derived: sum of 2 quarters · filed 2025-10-20 | $486.00K 10-Q · filed 2025-10-20 | -$186.00K derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-06-30 | -$3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $667.00K 10-Q · filed 2025-08-11 | $674.00K 10-Q · filed 2024-08-06 | -$5.00K derived: sum of 3 quarters · filed 2026-02-23 | $2.33M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $3.70M 10-Q · filed 2025-05-01 | $3.03M derived: sum of 2 quarters · filed 2026-02-23 | $5.36M derived: sum of 3 quarters · filed 2026-02-23 | $5.66M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2023-12-31 | -$672.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.66M derived: sum of 2 quarters · filed 2026-02-23 | $1.96M derived: sum of 3 quarters · filed 2026-02-23 | $2.26M 10-K · filed 2026-02-23 | ||
| 2023-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $2.63M derived: sum of 2 quarters · filed 2024-10-30 | $2.94M 10-Q · filed 2024-10-30 | $566.00K derived: sum of 4 quarters · filed 2025-02-24 | ||
| 2023-06-30 | $297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $605.00K 10-Q · filed 2024-08-06 | -$1.76M derived: sum of 3 quarters · filed 2025-02-24 | -$2.81M derived: sum of 4 quarters · filed 2025-02-24 | ||
| 2023-03-31 | $308.00K 10-Q · filed 2024-05-01 | -$2.06M derived: sum of 2 quarters · filed 2025-02-24 | -$3.10M derived: sum of 3 quarters · filed 2025-02-24 | -$6.58M derived: sum of 4 quarters · filed 2025-02-24 | ||
| 2022-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$3.41M derived: sum of 2 quarters · filed 2025-02-24 | -$6.89M derived: sum of 3 quarters · filed 2025-02-24 | -$4.13M 10-K · filed 2025-02-24 | ||
| 2022-09-30 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.52M derived: sum of 2 quarters · filed 2023-11-07 | -$1.76M 10-Q · filed 2023-11-07 | -$3.13M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | -$3.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$721.00K 10-Q · filed 2023-08-09 | -$2.08M derived: sum of 3 quarters · filed 2023-08-09 | -$3.10M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | $2.76M 10-Q · filed 2023-05-11 | $1.40M derived: sum of 2 quarters · filed 2023-05-11 | $376.00K derived: sum of 3 quarters · filed 2023-05-11 | $3.13M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$2.38M derived: sum of 2 quarters · filed 2023-03-09 | $371.00K derived: sum of 3 quarters · filed 2023-03-09 | -$1.71M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.74M derived: sum of 2 quarters · filed 2022-11-09 | -$347.00K 10-Q · filed 2022-11-09 | $3.14M derived: sum of 4 quarters · filed 2022-12-21 | ||
| 2021-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $672.00K 10-Q · filed 2022-08-11 | $4.16M derived: sum of 3 quarters · filed 2022-12-21 | $3.42M derived: sum of 4 quarters · filed 2022-12-21 | ||
| 2021-03-31 | -$2.08M 10-Q · filed 2022-05-11 | $1.41M derived: sum of 2 quarters · filed 2022-12-21 | $671.00K derived: sum of 3 quarters · filed 2022-12-21 | -$3.14M derived: sum of 4 quarters · filed 2022-12-21 | ||
| 2020-12-31 | $3.49M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $2.75M derived: sum of 2 quarters · filed 2022-12-21 | -$1.05M derived: sum of 3 quarters · filed 2022-12-21 | $1.64M 10-K/A · filed 2022-12-21 | ||
| 2020-09-30 | -$738.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$4.54M derived: sum of 2 quarters · filed 2021-11-15 | -$1.85M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.11M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | $2.70M 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | -$1.31M 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $283.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$521.00K 10-Q · filed 2020-11-16 | ||||
| 2019-06-30 | -$804.00K 8-K · filed 2020-09-29 | |||||
| 2019-01-31 | -$10.00K 10-K · filed 2021-03-31 | |||||
| 2018-01-31 | $2.57M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |